Introduction
Increased survival capacity is a key characteristic of breast cancer cells that contributes to the growth of primary tumors and the development of metastasis. A tumor cell needs to overcome a number of failsafe mechanisms to evade apoptosis and senescence programs, over-riding DNA damage checkpoints in order to continue proliferating. The survival of breast cancer cells can be stimulated by various growth factors, such as epidermal growth factor or insulin-like growth factor, acting through cell surface tyrosine kinase receptors and thus in understanding that their intracellular signaling is a central issue for the definition of future anticancer therapies (Gibbs, 2000; Bange et al., 2001) .
Fibroblast growth factor-2 (FGF-2) is the prototypic member of a family of over 20 related polypeptides, widely distributed in the organism and intimately involved in such diverse processes as cell growth and maturation, angiogenesis and tumorigenesis (Ornitz and Itoh, 2001) . The role of FGFs in tumor progression includes the stimulation of cancer cell growth and metastasis as well as angiogenesis (Ornitz and Itoh, 2001) . In breast cancer, the overexpression of FGF family members and FGF receptors has been reported in a significant percentage of breast tumors and cell lines (Dickson et al., 2000) . Moreover, high levels of FGFs have been detected in the sera from patients with breast cancer (Takei et al., 1994) . We and others have found that FGF-2 is a strong mitogen for breast cancer cell lines (Rahmoune et al., 1998; Nurcombe et al., 2000) and transfection by FGFs induces a progression towards an aggressive and metastatic phenotype McLeskey et al., 1993; Zhang et al., 1999; Suyama et al., 2002) , supporting a role for autocrine and paracrine involvement of FGFs during mammary malignant progression. Intriguingly, although FGF-2 has been reported to be antiapoptotic for several cell types, its potential prosurvival activity for breast cancer cells has never been investigated.
Growth factor-stimulated antiapoptotic signaling pathways generally involve the nuclear factor-kB (NFkB) transcription factor and/or the MAP-kinase pathways (Ballif and Blenis, 2001; Karin et al., 2004) . NF-kB activity is controlled by shuttling from the cytoplasm to the nucleus of NF-kB dimers retained in the cytoplasm through interaction with the inhibitors of NF-kB (IkBs). After stimuli, IkBs are phosphorylated by the activated IkB kinase (IKK) complex, inducing rapid ubiquitindependent degradation, allowing NF-kB dimers to translocate into the nucleus, where they stimulate expression of target genes (Karin et al., 2004) . IKK is composed of two catalytic subunits, IkB kinase-a (IKKa) and IkB kinase-b (IKKb) (also denominated IKK1 and IKK2), and an essential regulatory subunit, IKKg (NEMO). IKKb is mostly required for the canonical NF-kB pathway that depends on IkB degradation, and is described as directly activating p65 by phosphorylation. IKKa is involved in a noncanonical NF-kB pathway that regulates, at least, the RelB/p52 dimer (Karin et al., 2004) .
We show here that FGF-2 is a potent antiapoptotic for breast cancer cells as it can overcome the activity of various chemotherapeutic agents used in breast cancer therapy. Using a combination of pharmacological and molecular tools, we demonstrate that while p42/p44 MAP-kinases are not required, the antiapoptotic effect of FGF-2 relies on the activation of the phosphoinositide 3-kinase (PI3-kinase)/Akt pathway, resulting in the stimulation of NF-kB. We also demonstrated, using a proteomics-based approach, that NF-kB activation is mediated through interaction between Akt and IKKb.
Results

FGF-2 is antiapoptotic for breast cancer cells
To evaluate antiapoptotic activity of FGF-2 on breast cancer cells, three different breast cancer cell lines were treated by four different apoptogens in the presence or absence of FGF-2. The apoptotic cells exhibiting condensed and fragmented nuclei were visualized by Hoechst staining and counted under an Olympus-BH2 fluorescence microscope in randomly selected fields. At least 1000 cells were examined for each condition, and results were expressed as a ratio of the total number of cells counted. This method has previously been validated on the same cellular model by polyADP-ribose polymerase (PARP) cleavage detection (Descamps et al., 2001) . The results show that FGF-2 rescued breast cancer cells from apoptosis ( Figure 1 ). This survival effect was observed in all breast cancer cells and for all proapoptotic reagents used (C2, 5-fluorouracil, camptothecin, etoposide). Microscopic observation of apoptotic nuclei is shown in Figure 1a and the results of counting are represented in Figure 1b. FGF-2 antiapoptotic effect requires PI3K/Akt, but not p42/p44 MAP-kinases
To test the potential implication of PI3K/Akt and MAPK pathways in FGF-2 antiapoptotic activity, we performed experiments using pharmacological inhibitors, transfection with negative dominants or siRNA. FGF-2 antiapoptotic activity was not affected by the PD98059 MEK inhibitor (Figure 2a ). Western blotting with anti-phospho-p42/p44 antibody demonstrated that activation of these MAP-kinases by FGF-2 was effectively inhibited by PD98059 (Figure 2b ). Under the same experimental conditions, the mitogenic effect of FGF-2 for breast cancer cells was blocked by PD98059 (Vercoutter-Edouart et al., 2000) . Together, these results indicated that p42/p44 MAP-kinases, involved in FGF-2-induced mitogenesis, were not required for its antiapoptotic effect. On the other hand, treatment with PI3K inhibitors, LY294002 and wortmannin abolished FGF-2 antiapoptotic activity (Figure 2c) . A transient transfection of p110 negative dominant of PI3K (p110*(PI3K)Dk vector) also inhibited the survival effect of FGF-2 (Figure 2c) , further emphasizing the requirement of PI3K for FGF-2 antiapoptotic activity. Western blotting with antiphospho-Akt antibody showed that FGF-2-induced activation of Akt was effectively inhibited by wortmannin and LY294002 (Figure 2d ). It was noticeable that FGF-2 by itself did not stimulate Akt and that there was more activation of Akt with the simultaneous addition of C2. This has been further confirmed with other apoptogens, which were also required to obtain the induction of Akt by FGF-2 (Figure 2e ). By Western blotting (Figure 2e ), we have shown that the level of PI3K (p85) was not changed in any of our experimental conditions. In addition, the level of the phosphoinositide-dependent kinase (PDK1) was studied. Interestingly, the four apoptogens induced an upregulation of PDK-1 level. PDK-1 has previously been reported as a required activator of Akt during cell stimulation by growth factors (Mora et al., 2004) , and therefore, our data suggest that the apoptogens-induced upregulation of PDK1 is required to obtain Akt activation by FGF-2. Taken together, these data demonstrate that the FGF-2 antiapoptotic effect requires PI3K/Akt activation.
NF-kB activation induced by FGF-2 is PI3K/Akt dependent
The implication of NF-kB in the antiapoptotic effect of FGF-2 and its regulation by PI3K/Akt were studied by using a panel of negative dominants, siRNA and pharmacological inhibitors. We have shown that the NF-kB signaling pathway was stimulated by FGF-2 in C2-treated cells (Figure 3a ). In addition, this activation was inhibited by transfection with the repressor IkBm as well as by the NF-kB inhibitor SN50, p110(PI3K)*Dk PI3K negative dominant, Akt negative dominant, and siRNA against Akt (Figure 3a ). In accordance with data related to Akt activation (Figure 2 ), we have reported that there was always more activation of NF-kB with a combination of FGF-2 and C2 than with either compound by itself. The fact that NF-kB activation by growth factors requires cell stress has previously been reported (Bhakar et al., 1999; Descamps et al., 2001) and suggests that the PI3K/Akt/NF-kB pathway is more likely to be activated under cell-stress conditions. Cell treatment with SN50 and transfection by IkBm blocked FGF-2 antiapoptotic activity (Figure 3b ) (demonstrating that the antiapoptotic effect of FGF-2 required NF-kB activation). In contrast, transfection with the Figure 3c . These results, and particularly the siRNA-based experiments, indicate that FGF-2 rescued cells from apoptosis by stimulating the NF-kB pathway via PI3K/Akt activation.
IKKb is phosphorylated by Akt upon FGF-2 stimulation
The potential interaction between Akt and IKK was tested by co-immunoprecipitation and Western blotting. We demonstrated that FGF-2, in the presence of C2, induced the formation of a complex between Akt and IKK ( Figure 4a ). Importantly, an addition of wortmannin abolished the FGF-2-induced IKK/Akt interaction, demonstrating a PI3K requirement for this activation.
In addition, Western blotting with anti-phospho-(Ser/Thr) Akt substrate (PAS) antibody showed a phosphorylation of IKK by Akt upon FGF-2 activation ( Figure 4a ). The PAS antibody recognizes the consensus site for Akt phosphorylation only when it is phosphorylated, indicating that IKK is a substrate of Akt, which is activated by FGF-2 stimulation. For further precision regarding the isoform of IKK involved in Akt-mediated antiapoptotic signaling, we analysed the co-immunoprecipitate using a proteomicsbased approach. Two-dimensional (2D) gel electrophoresis of Akt-co-immunoprecipitated material, obtained from FGF-2-stimulated cells, revealed an increase in intensity of a spot in the gel area of molecular weight and an isoelectric point corresponding to IKK ( Figure 4b ). This spot, detected by Colloidal blue staining, was identified after trypsin digestion and MALDI-TOF mass spectrometry. The spectrum obtained ( Figure 4c ) was used for database searching and allowed the identification of the beta form of IKK (IKKb) (Figure 4d ). Major peaks of the spectrum corresponded to tryptic fragments of IKKb, with a To evaluate the MAP-kinase activation, protein extracts were prepared from cells treated as described above, before SDS-PAGE and Western blotting with anti-phospho-p42/p44 antibody. (c) In pharmacological inhibitor testing, cells were serum deprived, pretreated with LY294002 or wortmannin, and then treated with C2, with or without FGF-2. Cells were fixed and apoptotic nuclei were observed after Hoechst staining. For transfection, cells were cotransfected with EGFP-C1-and p110(PI3K)*Dk-carrying vectors. Controls were performed with EGFP-C1 vector and pCDNA3 empty vector. After serum starvation, cells were treated with C2 with or without FGF-2, then fixed and the proportion of apoptotic nuclei in GFP-positive cells was determined after Hoechst staining. (d) To measure the phosphorylation of Akt induced by FGF-2 in C2-stimulated cells, protein extracts were prepared from cells treated in the different conditions before Western blotting with anti-phospho-Akt antibody. To assess the cellular content of total Akt, the membrane was rehybridated with anti-Akt antibody. (e) Effects of FGF-2 on phosphorylation of Akt, PDK-1 level and PI3K (p85) level were studied by Western blotting in MCF-7 cells treated with different apoptogens: C2 (10 mM), 5-fluorouracil (5FU, 100 mM), camptothecin (Campto., 0.1 nM) and etoposide (Eto., 10 mM) Akt/IKKb interaction in FGF-2 antiapoptotic activity F Vandermoere et al precise correspondence between submitted and calculated masses.
IKKb is required to FGF-2-induced activation of NF-kB and cell survival
The implication of IKKb in FGF-2-induced NF-kB activation was tested by siRNA against IKKb and NFkB activity assay. Hoescht staining was performed to quantify cell survival. MCF-7 cells were treated with siRNA against IKKb. The testing of several concentrations of siRNA indicated 150 nM as the most efficient concentration (Figure 5a ), and this was therefore used in the assay of NF-kB activity and cell survival. Western blotting against IKKa was used to verify the specificity of our siRNA. Cell treatment with siRNA against IKKb resulted in a blocking of both FGF-2-induced NF-kB activity (Figure 5b ) and cell survival (Figure 5c ). These data show the functional involvement of IKKb in the activation of NF-kB and the subsequent stimulation of cell survival by FGF-2.
Discussion
We show here that FGF-2 is antiapoptotic for breast cancer cells and is able to counteract cell death-inducing factors such as the C2 ceramide and several chemotherapeutic agents. The antiapoptotic activity of FGF-2 has been largely described in noncancerous cells of various origins (Ornitz and Itoh, 2001) , and this factor is also known as a strong survival promoter of several cancer cells, such as in the lung (Pardo et al., 2002) , T lymphoma (Murphy et al., 2001 ) and prostate (Polnaszek et al., 2003) . In breast cancer, with the exception of one study showing that FGF-2 can promote growth inhibition and apoptosis under particular experimental conditions (Fenig et al., 1997) , all studies indicate a strong promotion of tumor growth and metastasis McLeskey et al., 1993; Rahmoune et al., 1998; Zhang et al., 1999; Nurcombe et al., 2000; Suyama et al., 2002) , and our present data emphasize this idea by showing a direct stimulation of breast tumor cell survival by FGF-2. Given that FGF-2 is naturally present in breast tumors and is produced by mammary cells (Dickson et al., 2000) , our results suggest that chemotherapeutic agents used in breast cancer treatment might be subject to a potential endogenous inhibition by FGF-2. Therefore, strategies based on FGF inhibition, such as with glycosaminoglycans or tyrosine kinase inhibitors (Ornitz and Itoh, 2001 ; Manetti and Botta, Our results show that p42/p44 MAP-kinases are not necessary for FGF-2-mediated antiapoptotic effect in breast cancer cells, and although one might regard this as unusual, a lack of p42/p44 involvement in survival signaling has already been reported (Creedon et al., 1996; Ajenjo et al., 2000; Descamps et al., 2001) . In contrast, we found the PI3K/Akt signaling to be necessary for the FGF-2 antiapoptotic effect. PI3K was first identified as an enzymatic activity associated with the Rous sarcoma pp60v-src protein and the polyomamiddle T antigen that is essential for the transforming activity of these oncogenes, and Akt was also found to be a virus-transduced oncogene (Luo et al., 2003) . The PI3K/Akt pathway is a key regulator of cell survival through multiple downstream targets and it has been shown that Akt can promote cell survival by indirectly activating the prosurvival transcription factor NF-kB (Ozes et al., 1999; Romashkova and Makarov, 1999) . Our results are the first to demonstrate the FGF-2-activated PI3K/Akt/NF-kB signaling pathway in breast cancer cells.
Given that NF-kB is known to be subject to activation by IKK, and as we have shown an Aktmediated stimulation of NF-kB, we investigated the possibility of a direct activation of IKK by Akt. Coimmunoprecipitation indicated that Akt interacted with IKK upon FGF-2 stimulation, and our proteomic analysis has allowed the identification of the beta form of IKK (IKKb) as being specifically involved. During the last several years, proteomics has progressively evolved from a purely descriptive approach of cellular protein content to a comprehensive way of studying protein-protein interaction and this is of considerable interest for analysing the molecular mechanism of breast carcinogenesis (Hondermarck, 2003) . Analysis of MAL-DI-TOF tryptic fragment masses unequivocally designated the b form of IKK, with a robust correspondence between measured and calculated masses. Therefore, our results indicate that, in breast cancer cells, IKKb is a signaling partner and a substrate of Akt phosphorylation activity. The fact that IKKb was detected after colloidal blue staining of 2D gels of Akt-co-immunoprecipitated material indicated that a substantial Figure 4 Akt/IKKb interaction is induced by FGF-2 stimulation. (a) Protein extracts were prepared from MCF-7 cells treated by C2, with or without FGF-2 in the presence or absence of wortmannin. SDS-PAGE of co-immunoprecipitated material with anti-Akt or anti-IKK antibodies was followed by Western blotting with anti-Akt, anti-IKK or anti-phospho-Akt substrate (PAS) antibodies. (b) Akt-co-immunoprecipitated proteins were prepared from cells pretreated with C2 (incubated with FGF-2 or not) and separated by 2D electrophoresis. The gels were stained with colloidal blue and the portion of gel corresponding to MW and pI of IKK was selected. The spot found regulated in the presencee of FGF-2 was cut out of the gel before analysis by mass spectrometry. (c) The spot was digested with trypsin and peptide masses fingerprint was obtained using MALDI-TOF mass spectrometry. (d) Database searching using MS-Fit and Profound allowed the identification of the spot as the beta form of IKK (IKKb) Akt/IKKb interaction in FGF-2 antiapoptotic activity F Vandermoere et al amount of IKKb actually interacted with Akt. Interestingly, the blocking of NF-kB and cell survival that we have observed with siRNA targeted against IKKb shows the functional involvement of IKKb in the FGF-2-mediated antiapoptotic signaling. Importantly, it has previously been shown that Akt directly phosphorylates the a form of IKK (IKKa) under stimulation by tumor necrosis factor (TNF) (Ozes et al., 1999) , epidermal growth factor and insulin-like growth factor-I (Kulik et al., 1997) and platelet-derived growth factor (Romashkova and Makarov, 1999) . Most previous studies on NF-kB activation through Akt/IKK signaling have focused their attention on the alpha form of IKK (IKKa). Our present work demonstrates that IKKa is not the only substrate of Akt, and that, in breast cancer cells, the FGF-2-mediated activation of NF-kB involves the phosphorylation of IKKb by Akt.
The Akt-phosphorylated consensus site is commonly defined as RXRXX(S/T) (Alessi et al., 1996; Obata et al., 2000) . In our study, we demonstrated that FGF-2 stimulates phosphorylation of IKKb on a site recognized by the PAS antibody. The IKKb phosphorylation site closest to Akt consensus is KERLGT23 (http:// scansite.mit.edu/motifscanner). In fact, the primary sequence of IKKb does not contain the consensus sequence predicted for an Akt substrate: the arginine at position À5 is replaced by a lysine, another basic residue. However, IKKb encodes a peptide sequence that is consistent with a pattern of other Akt-phosphorylated targets where arginine at position À5 is not present as insulin-response element-binding protein 1(KERCQS1036) (Villafuerte et al., 2004) , CREB LSRRPS133Y (Du and Montminy, 1998) and ATPcitrate lyase (TPAPSRTAS454F) (Berwick et al., 2002) . The PAS antibody that we have used was raised against Akt RXRXX(pS/pT) consensus sequence, but the arginine in the À5 position is not strictly required for phosphoprotein recognition, as was described for the ATP-citrate lyase (Berwick et al., 2002) . Therefore, the arginine at position À5 is not too essential for Akt phosphorylation activity. The RXRXX(S/T) consensus Akt phosphorylation site has been derived from a number of studies that utilized short synthetic peptides (Alessi et al., 1996; Obata et al., 2000) . In vitro Akt phosphorylation of short peptides may not represent the phosphorylation of intact proteins in vivo. Tertiary topology could also be important in making a 'suboptimal' site amenable to phosphorylation by Akt (Lawlor and Alessi, 2001 ). Lawlor and co-workers have postulated the existence of an Akt docking site on some substrates in a manner analogous to the d-domain on cJun, which acts as a JNK docking site. S6K1/2 phosphorylation mediates the mTOR protein-induced cell growth (Fingar and Blenis, 2004) . Most growth factors and cytokines activate mTOR and its downstream target S6 kinase by a PI3K/Akt-dependent pathway. As IKKb includes the strict S6K consensus site (KXRXXS/T), we can also postulate that IKKb is phosphorylated by the downstream S6K effector of the Akt pathway. Several groups have found that PI3K/ Akt-mediated activation of mTOR also leads to attenuation of insulin signaling. They have demonstrated that activation of the PI3K/Akt/mTOR pathway by PDGF (Li et al., 1999) , TNF-a (Ozes et al., 2001) or insulin (Greene et al., 2003; Carlson et al., 2004) leads to IRS-1 and/or IRS-2 serine phosphorylation and downregulation. As IRS-1 is a multidocking protein adaptor that allows PI3K activation, its inhibition by S6K constitutes a negative feedback loop for the PI3K/Akt pathway. We show here that Akt physically interacts with IKKb under FGF-2 stimulation, and therefore IKKb could potentially constitute a common substrate for the Akt/S6K complex.
Among growth factors able to stimulate breast cancer cell survival, insulin-like growth factor-I and epidermal growth factor were the first to be identified. More recently, it has been shown that the prototypical neurotrophic factor, nerve growth factor, is also a potent antiapoptotic for breast cancer cells (Descamps et al., 2001) , via the p75 NTR neurotrophin receptormediated activation of NF-kB. Our present data, obtained with FGF-2, emphasize that NF-kB is a central signaling element for breast cancer cell survival, and although there is a diversity in the pathways leading to its activation, PI3K/Akt increasingly appears to be crucially involved. In conclusion, targeting the PI3K/ Akt/IKKb pathway appears as a rational and promising way for the development of future strategies against breast cancer.
Materials and methods
Materials
Cell culture reagents were purchased from Biowhittaker (France). Recombinant human FGF-2 was from R&D systems (France). PD98059 (inhibitor of MEK1 and 2), wortmannin and LY294002 (PI3K inhibitors) were from Calbiochem (France). SN50 (NF-kB inhibitor peptide) was from TEBU (France). Mouse monoclonal anti-p42/p44 MAP-kinases antibody, mouse monoclonal anti-(phospho) Akt antibody, rabbit anti-phospho-(Ser/Thr) Akt substrate antibody, anti-PDK1 antibody and anti-IKK antibody were from Cell Signaling Technology (Ozyme, France). The C2 ceramide analogue (Nacetyl-D-sphingosine), 5-fluorouracil, camptothecin, etoposide, Hoechst 33258, DMSO and G250 brilliant blue were from Sigma (France). b-Galactosidase and luciferase reporter detection kits were from Tropix (France). ExGen 500 (transfection reagent) was from MBI-Fermentas (Germany) and Opti-minimum essential medium (MEM) from Life Technologies (France). b-Galactosidase (pCMV-b-gal), p3NF-kB activation luciferase reporter (NF-kB-luc) were from Stratagene (France) and the green fluorescent protein cDNAcarrying vector (EGFP-C1) was from Clontech (France). PI3K negative dominant (p110(PI3K)*Dk) and mutant IkBa (IkBm) were provided by Dr Jean Coll (Institut de Biologie de Lille, France). The 2D electrophoresis reagents were purchased from Proteomic solutions (France) and the porcine trypsin from Promega (France). The siIMPORTERt siRNA transfection reagent and the rabbit anti-p85PI3K and anti-actin antibodies were from Upstate (UK) and siRNA SMART pools from Ambion (UK).
Cell culture
Breast cancer cell lines MCF-7, T47-D and BT-20 were obtained from the American Type Culture Collection and routinely grown as monolayers. Cells were grown at 371C in a humidified atmosphere of 5% CO 2 in minimal essential medium (MEM-Earle's salts) supplemented with 20 mM Hepes, 2 g/l sodium bicarbonate, 2 mM Lglutamine, 1% nonessential amino acids, 10% fetal calf serum (FCS), 100 U/ml penicillin/streptomycin and 50 mg/ml gentamycin.
Determination of the percentage of apoptotic cells
Apoptosis of MCF-7, T47-D and BT-20 breast cancer cells was obtained by treatment for 24 h with a C2 ceramide analogue (10 mM), or 3 h with 5-fluorouracil (100 mM), camptothecin (0.1 nM) or etoposide (10 mM). The antiapoptotic effect of FGF-2 was evaluated at 5 ng/ml in a serum-free medium; this concentration was chosen after a dose-effect study (data not shown). After 24 h, cells were fixed with cold methanol (À201C) for 10 min and washed twice with phosphate-buffered saline (PBS) before staining with 1 mg/ml Hoechst 33258 (10 min at room temperature) in the dark. Then, the cells were washed with PBS and mounted with coverslips using glycergel (Dako, Denmark). Those apoptotic cells exhibiting condensed and fragmented nuclei were counted under an inverted DMIRB microscope (Leı¨ca, Germany) with UV excitation at 360/40 nm in randomly selected fields. At least 1000 cells were examined for each condition, and results were expressed as a percentage of apoptotic cells observed per total number of cells counted.
Analysis of MAP-kinases and Akt activation
Proteins were extracted from MCF-7 cells. Then, after 15 min of 5 ng/ml FGF-2 stimulation in 100 mM pervanadate, the cells were rinsed with pH 7.5 PBS and scratched in lysis buffer (150 mM NaCl, 50 mM Tris (pH 7.5), 0.1% SDS, 1% Nonidet P-40, 100 mM sodium orthovanadate). After centrifugation (10 000 g, 5 min), proteins were quantified using Bradford's method (Bio-Rad, France). Equal quantities of total proteins for each condition were separated by SDS-PAGE after heating (951C, 5 min) in Laemmli buffer. After electroblotting, nitrocellulose membranes were blocked by Tris-buffered saline (TBS), 0.1% Tween-20 (containing 3% bovine serum albumin for MAP-kinases assay or 5% milk for Akt) and probed with the mouse monoclonal anti-phospho-p42/p44 MAP-kinase antibody, the mouse monoclonal anti-phospho Akt antibody (Cell Signaling Technology, France), the anti-PDK-1 or the anti-p85 (PI3K) overnight at 41C. Then, the membranes were rinsed, incubated with biotin-conjugated anti-mouse or antirabbit immunoglobulin G (for 2 h, at room temperature), rinsed and incubated with avidin-peroxidase. After extensive washes, the reaction was revealed using the Super Signal West Pico chemoluminescent substrate (Interchim, France) with Kodak X-Omat AR film.
NF-kB activation assay
MCF-7 cells were incubated for 5 h in 1 ml of Opti-MEM transfection medium containing 5 ml ExGen 500 transfection reagent, 500 ng p3NF-kB luciferase reporter vector, 150 ng pCMV b-galactosidase normalizator vector with either 150 ng of IkBm-carrying vector or an empty vector. Cells were grown in 10% FCS MEM and rinsed in serum-free medium (for 2 h) before incubation for 24 h in serum-free medium in the presence or absence of 5 ng/ml FGF-2, with or without 10 mM C2. Cells were then rinsed with PBS and lysed with reporter lysis buffer. Pellets were discarded after centrifugation (10 000 g, for 5 min). Luciferase and b-galactosidase activities of 20 ml sample were quantified using a luciferase assay kit and galactolight kit, respectively, and a lumat LB 9501 luminometer (Berthold, France). The NF-kB activity was normalized with the pCMV b-gal control vector coding the b-galactosidase protein.
Cell transfection
MCF-7 cells were incubated for 5 h in 1 ml of Opti-MEM transfection medium containing 5 ml ExGen 500 transfection Akt/IKKb interaction in FGF-2 antiapoptotic activity F Vandermoere et al reagent, 600 ng EGFP-C1 with either 150 ng IkBm, 200 ng p110(PI3K)*Dk or the 200 ng pCDNA3 of the corresponding empty vector. Transfected cells were then grown for 24 h in 10% FCS MEM and rinsed for 2 h in serum-free medium before a 5 ng/ml FGF-2 treatment in the presence or absence of 10 mM C2 for another 24 h before subsequent experimentation (apoptotic cells counting, NF-kB activity measurement or immunoprecipitation and Western blotting).
For transfection with siRNA (targeted against Akt or IKKb), MCF-7 cells were incubated for 6 h in serum-free medium with a mixture of MEM, 5 ml transfectant (siIMPOR-TER s ) and 150 nM SMART pools siRNA, according to the manufacturer's instructions (Upstate, UK). Then, 10% FCS were added directly to the medium. After 72 h, the cells were rinsed for 2 h in serum-free medium before treatment with FGF-2 and/or apoptogens and a measurement of both NF-kB activation and cell survival was carried out as described above. The decrease in Akt or IKKb protein levels was checked by Western blotting with anti-Akt or anti-IKKb antibody.
Co-immunoprecipitation and Western blot
MCF-7 cells were plated at 500 000 cells per 100 mm dish in complete medium and at 70% confluence, and they were rinsed for 3 h in serum-free medium. Then, cells were treated with 10 mM C2 for 24 h before stimulation with 5 ng/ml FGF-2 for 15 min. After two washes in ice-cold PBS, cells were lysed on ice with lysis buffer (50 mM Tris (pH 7.5); 150 mM NaCl; 1% Nonidet P-40; 1 mM PMSF; 1 mM orthovanadate; 1 mM sodium pyrophosphate; 10 mg/ml leupeptin; 10 mg/ml aprotinin), centrifuged (10 000 g, 2 min) and the supernatant was used for Akt immunoprecipitation. Protein concentration was determined using Bradford's method and 1 mg of total proteins was used for immunoprecipitation. Akt and interacting proteins were co-immunoprecipitated with 5 mg of anti-Akt antibody per mg of total proteins using dynabeads protein G (Dynalbiotech, France). Proteins were solubilized in Laemmli buffer and separated by SDS-PAGE. After electroblotting, nitrocellulose membranes were blocked by TBS, 0.1% Tween (containing either 3% bovine serum albumin for IKK detection or 5% milk for Akt Western blotting) and probed, overnight at 41C, with the mouse monoclonal anti-IKK antibody (1/2000) or the mouse monoclonal Akt antibody (1/1000) or the rabbit anti-phospho-(Ser/Thr) Akt substrate antibody (1/2000) (Cell Signaling Technology, France). Then, the membranes were rinsed, incubated with peroxidaseconjugated anti-mouse or anti-rabbit immunoglobulin G (1 h, room temperature). After extensive washes, the reaction was revealed using the Super Signal West Pico chemoluminescent substrate (Pierce, France) with Kodak X-Omat AR film.
2D electrophoresis
Akt and interacting proteins were co-immunoprecipitated as described above and proteins were solubilized in SDS solution (0.3% SDS and 1% b-mercaptoethanol), and warmed for 3 min at 951C. 2D electrophoresis was performed as described previously (Vercoutter-Edouart et al., 2001) with the Investigator 2D Electrophoresis System (ESA, France). IEF was performed in rod gels containing 2% of each pH 4-8 and pH 3-10 carrier ampholyte, at 20 000 V h. After IEF, the gels were equilibrated for 2 min in 0.3 M Tris base (0.075 M Tris-HCl (pH 9.0), 3% SDS, 50 mM DTT and 0.01% bromophenol blue). The second separation was performed using 10% SDS-PAGE. After migration, the gels were fixed (50% ethanol; 0.2 M orthophosphoric acid) and proteins were detected with colloidal blue staining (1 h in a mixture of 30% methanol, 0.2 M orthophosphoric acid and 170 g/l ammonium sulfate, before incubation in the same solution to which 0.66 g/L of G250 brilliant blue had been added).
Trypsin digestion, mass spectrometry and database searching
Protein identification was performed as described previously (Vercoutter-Edouart et al., 2001) . The spot of interest was cut out from 2D gel and washed three times with 300 ml of a 100 mM ammonium carbonate/acetonitrile (ACN) 1 : 1 (v/v) solution for 20 min under shaking. The piece was dried with three baths of 150 ml ACN (for 15 min, at room temperature). Enzymatic cleavage was initiated by reswelling the gel piece in 150 ml ammonium carbonate solution (50 mM) containing 7.5 U of trypsin. After absorption of the protease, 50 mM ammonium carbonate solution was added. Digestion was carried out for 12 h at 371C. The liquid was collected and the resulting peptides recovered after two elutions from gel with a solution containing 45% ACN/10% formic acid. To recover the very hydrophobic peptides, a third elution with 95% ACN/ 5% formic acid was performed. The extract was finally dried using a Speed Vac-concentrator (Eppendorf, France). Peptides were solubilized in ACN/H 2 O (1 : 1) containing 1% formic acid, of which 1 ml was applied directly to the target with 1 ml of 2.5 dihydroxybenzoic acid matrix solution (10 mg/ml in methanol/water, 7 : 3). A Matrix-Assisted Laser Desorption Ionisation-Time Of Flight (MALDI-TOF) analysis of trypsin digests was performed on a Voyager DE-STR Pro instrument (Applied Biosystems, France) in the positive reflector ion mode. About 150 laser shots were accumulated to obtain a final spectrum. Mass measurements were made after peak smoothing and internal calibration, using the monoisotopic mass of the two autolysis trypsin fragment ions at m/z 842.510 and 2211.105. Protein sequence database searching was performed with MS-Fit (http://prospector.ucsf.edu/ ucsfhtml4.0/msfit.htm) and Profound (http://prowl.rockefeller. edu/profound_bin/WebProFound.exe).
